Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Krystal Biotech participates in a conference call with Cowen » 12:25
05/26/20
05/26
12:25
05/26/20
12:25
KRYS

Krystal Biotech

$53.39 /

+0.385 (+0.73%)

Biotech Analyst Baral…

Biotech Analyst Baral holds a conference call with management will be held on May 26 at 1 pm hosted by Cowen.

ShowHide Related Items >><<
KRYS Krystal Biotech
$53.39 /

+0.385 (+0.73%)

KRYS Krystal Biotech
$53.39 /

+0.385 (+0.73%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$53.39 /

+0.385 (+0.73%)

KRYS Krystal Biotech
$53.39 /

+0.385 (+0.73%)

Conference/Events
Krystal Biotech participates in a conference call with Cowen » 04:55
05/26/20
05/26
04:55
05/26/20
04:55
KRYS

Krystal Biotech

$53.00 /

-0.71 (-1.32%)

Biotech Analyst Baral…

Biotech Analyst Baral holds a conference call with management will be held on May 26 at 1 pm hosted by Cowen.

ShowHide Related Items >><<
KRYS Krystal Biotech
$53.00 /

-0.71 (-1.32%)

KRYS Krystal Biotech
$53.00 /

-0.71 (-1.32%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$53.00 /

-0.71 (-1.32%)

KRYS Krystal Biotech
$53.00 /

-0.71 (-1.32%)

Conference/Events
Krystal Biotech participates in a conference call with Cowen » 14:12
05/22/20
05/22
14:12
05/22/20
14:12
KRYS

Krystal Biotech

$53.47 /

-0.24 (-0.45%)

Biotech Analyst Baral…

Biotech Analyst Baral holds a conference call with management will be held on May 26 at 1 pm hosted by Cowen.

ShowHide Related Items >><<
KRYS Krystal Biotech
$53.47 /

-0.24 (-0.45%)

KRYS Krystal Biotech
$53.47 /

-0.24 (-0.45%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$53.47 /

-0.24 (-0.45%)

  • 19
    May
KRYS Krystal Biotech
$53.47 /

-0.24 (-0.45%)

Syndicate
Krystal Biotech 2.3M share Spot Secondary priced at $55.00 » 06:01
05/19/20
05/19
06:01
05/19/20
06:01
KRYS

Krystal Biotech

$56.65 /

-2.55 (-4.31%)

he deal range was…

he deal range was $55.00-$56.00. Cowen and Evercore ISI acted as joint book running managers for the offering.

ShowHide Related Items >><<
KRYS Krystal Biotech
$56.65 /

-2.55 (-4.31%)

KRYS Krystal Biotech
$56.65 /

-2.55 (-4.31%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$56.65 /

-2.55 (-4.31%)

  • 19
    May
KRYS Krystal Biotech
$56.65 /

-2.55 (-4.31%)

Syndicate
Krystal Biotech announces common stock offering, no amount given » 16:19
05/18/20
05/18
16:19
05/18/20
16:19
KRYS

Krystal Biotech

$56.40 /

-2.8 (-4.73%)

Krystal Biotech announced…

Krystal Biotech announced that it has commenced an underwritten public offering of its common stock. The company currently intends to use the net proceeds from this offering, if any, together with its existing cash, cash equivalents and short-term investments: (i) to advance KB103 into and through a Phase 3 clinical trial; (ii) to advance the clinical development of KB105; (iii) to advance the pre-clinical and clinical development of KB104, KB301 and KB407; (iv) to complete development of a good manufacturing practices certified manufacturing facility for scale-up production of the company's pipeline compounds and commencement of operations of that facility; and (v) the balance for working capital and general corporate purposes, including research and development expenses and capital expenditures. Cowen and Evercore ISI are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
KRYS Krystal Biotech
$56.40 /

-2.8 (-4.73%)

KRYS Krystal Biotech
$56.40 /

-2.8 (-4.73%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$56.40 /

-2.8 (-4.73%)

KRYS Krystal Biotech
$56.40 /

-2.8 (-4.73%)

Conference/Events
Society for Investigative Dermatology to hold virtual meeting » 05:55
05/16/20
05/16
05:55
05/16/20
05:55
KRYS

Krystal Biotech

$59.20 /

-0.23 (-0.39%)

2020 SID Annual Virtual…

2020 SID Annual Virtual Meeting will be held on May 13-16.

ShowHide Related Items >><<
KRYS Krystal Biotech
$59.20 /

-0.23 (-0.39%)

KRYS Krystal Biotech
$59.20 /

-0.23 (-0.39%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$59.20 /

-0.23 (-0.39%)

KRYS Krystal Biotech
$59.20 /

-0.23 (-0.39%)

Conference/Events
Society for Investigative Dermatology to hold virtual meeting » 04:55
05/15/20
05/15
04:55
05/15/20
04:55
KRYS

Krystal Biotech

$59.43 /

+1.73 (+3.00%)

2020 SID Annual Virtual…

2020 SID Annual Virtual Meeting will be held on May 13-16.

ShowHide Related Items >><<
KRYS Krystal Biotech
$59.43 /

+1.73 (+3.00%)

KRYS Krystal Biotech
$59.43 /

+1.73 (+3.00%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$59.43 /

+1.73 (+3.00%)

KRYS Krystal Biotech
$59.43 /

+1.73 (+3.00%)

Hot Stocks
Krystal Biotech announces interim results from Phase 1/2 trial of KB105 » 08:22
05/14/20
05/14
08:22
05/14/20
08:22
KRYS

Krystal Biotech

$57.70 /

-1.13 (-1.92%)

Krystal Biotech announced…

Krystal Biotech announced interim results for a first-in-human Phase 1/2 placebo controlled clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis being presented at the Society for Investigative Dermatology annual meeting. Following today's results, Krystal plans to enroll pediatric patients in the Phase 2 portion of the clinical trial. The interim results summarize data from three adult patients, aged 39, 24, and 20 years old who participated in a randomized placebo-controlled study to receive either topical KB105 or placebo in circular skin areas of 20cm. The KB105 treated areas were biopsied following a single treatment to assess onset of expression and following multiple repeat administrations to assess durability and efficacy of repeat dosing. Safety data from all three patients showed that repeat dosing with KB105 was well-tolerated with no drug related adverse events and no immune response to the HSV modified vector or TGM1. Also, no vector shedding or systemic exposure was detected in any of the three patients. KB105-treated areas showed clearly detectable TGM-1 expression in all treated sites following initial and repeat administration. KB105-expressed TGM1 was correctly localized in the epidermis, co-localizing with loricrin, and was functionally active. QPCR, immunofluorescence and in situ analysis demonstrated similar delivery efficacy of TGM1 DNA from single and repeat administration. Phenotypic evaluation was limited by small treatment areas, but KB105 treated areas showed reduced reversion to disease phenotype. Micro-needling pre-treatment did not show any significant increase in expression when compared to direct topical administration without micro-needling, especially after repeated application. Krystal plans to initiate a Phase 2 study in pediatric patients in the second half of 2020. The Company hopes to incorporate the new ichthyosis severity score scale into studies for clinical validation.

ShowHide Related Items >><<
KRYS Krystal Biotech
$57.70 /

-1.13 (-1.92%)

KRYS Krystal Biotech
$57.70 /

-1.13 (-1.92%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$57.70 /

-1.13 (-1.92%)

KRYS Krystal Biotech
$57.70 /

-1.13 (-1.92%)

Conference/Events
Society for Investigative Dermatology to hold virtual meeting » 04:55
05/14/20
05/14
04:55
05/14/20
04:55
KRYS

Krystal Biotech

$57.70 /

-1.13 (-1.92%)

2020 SID Annual Virtual…

2020 SID Annual Virtual Meeting will be held on May 13-16.

ShowHide Related Items >><<
KRYS Krystal Biotech
$57.70 /

-1.13 (-1.92%)

KRYS Krystal Biotech
$57.70 /

-1.13 (-1.92%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$57.70 /

-1.13 (-1.92%)

KRYS Krystal Biotech
$57.70 /

-1.13 (-1.92%)

Conference/Events
Society for Investigative Dermatology to hold virtual meeting » 08:41
05/13/20
05/13
08:41
05/13/20
08:41
KRYS

Krystal Biotech

$58.83 /

-1.38 (-2.29%)

2020 SID Annual Virtual…

2020 SID Annual Virtual Meeting will be held on May 13-16.

ShowHide Related Items >><<
KRYS Krystal Biotech
$58.83 /

-1.38 (-2.29%)

KRYS Krystal Biotech
$58.83 /

-1.38 (-2.29%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$58.83 /

-1.38 (-2.29%)

KRYS Krystal Biotech
$58.83 /

-1.38 (-2.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.